Hudson Bay Capital Management
ZVRA icon

Hudson Bay Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Hudson Bay Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-723,076
Closed -$9.27M – 1093
2021
Q2 		$9.27M Buy
+723,076
New +$7.77M 0.11% 150

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hudson Bay Capital Management's ZVRA Position: Q3 2021 in Review

Hudson Bay Capital Management sold out of Zevra Therapeutics (ZVRA) in Q3 2021, closing a stake of 723,076 shares — an estimated $9.27M sold.

Hudson Bay Capital Management first reported a position in ZVRA in Q2 2021 and held it in 1 quarter. The position peaked at $9.27M in Q2 2021. 71 funds tracked by Wall St. Rank hold ZVRA as of Q3 2021.

  • Hudson Bay Capital Management reported no remaining Zevra Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Hudson Bay Capital Management sold 723,076 Zevra Therapeutics shares in Q3 2021, an estimated $9.27M.
  • Hudson Bay Capital Management first reported a position in Zevra Therapeutics in Q2 2021 and held it in 1 quarter.
  • Hudson Bay Capital Management's Zevra Therapeutics position peaked at $9.27M in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2021.

Based on Hudson Bay Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.